714 related articles for article (PubMed ID: 26014296)
21. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
[TBL] [Abstract][Full Text] [Related]
23. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
[TBL] [Abstract][Full Text] [Related]
24. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
25. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Mehta DA; Hay JW
Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
28. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
29. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
[TBL] [Abstract][Full Text] [Related]
30. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T
Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029
[TBL] [Abstract][Full Text] [Related]
31. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Uyl-de Groot CA; Stupp R; van der Bent M
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
[TBL] [Abstract][Full Text] [Related]
33. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
35. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Messali A; Hay JW; Villacorta R
Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
[TBL] [Abstract][Full Text] [Related]
36. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
Li H; Li X; Xie F
Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
[TBL] [Abstract][Full Text] [Related]
37. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
38. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
[TBL] [Abstract][Full Text] [Related]
39. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
40. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Henaine AM; Paubel N; Ducray F; Diebold G; Frappaz D; Guyotat J; Cartalat-Carel S; Aulagner G; Hartmann D; Honnorat J; Armoiry X
J Clin Pharm Ther; 2016 Feb; 41(1):47-53. PubMed ID: 26748577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]